 Genfit SA NASDAQ: GNFT shares shot up 150 in the after-hours trading today. What Happened: The France-based late-stage biopharmaceutical company said in the after-hours Tuesday that positive results from the Phase 2 trial evaluating elafibranor in patients with Primary Biliary Cholangitis have been published. 